EndoCyclic Therapeutics is at the forefront of developing innovative, non-hormonal therapeutic and diagnostic agents specifically targeting oncology and women's health. Their approach centers on the use of precision pH-sensitive peptides that are designed to selectively target diseased cells, such as those associated with colon and endometrial cancers, as well as endometriosis. This targeted dual-mode solution ensures that therapeutic interventions and diagnostic imaging are confined to affected tissues, thereby enhancing treatment efficacy while minimizing side effects. The company’s key products include investigational therapeutics like ENDO-205 and ENDO-995, aimed at treating endometriosis and colon cancer, respectively, alongside diagnostic agents such as ENDO-210 and ENDO-311, which are designed for non-invasive imaging of these conditions.

The technology employed by EndoCyclic is characterized by its ability to penetrate cells and bind to unique intracellular targets found exclusively in diseased tissues. This specificity not only maximizes therapeutic effectiveness but also preserves fertility, addressing the root causes of diseases rather than merely alleviating symptoms. Their imaging agents, particularly ENDO-210, promise to revolutionize the detection of endometriosis by providing unprecedented clarity in identifying sub-millimeter lesions that are typically undetectable with current imaging technologies. Through these advancements, EndoCyclic aims to transform the landscape of treatment and diagnosis in women's health and oncology.

United States

EndoCyclic Therapeutics is a biopharmaceutical company engaged in the development of the first non-hormone therapeutic for endometriosis.

EndoCyclic

Company Details